1:05pm (EST) The bulls are pushing resistance once again after a number of companies beat earnings expectations which has helped offset weaker-than expected economic data. Although the market has moved slightly below its session highs, the momentum is there for the bulls to close above our price targets. The Commerce Department said wholesale inventories fell 0.2% to $425.5 billion after increasing 1.9% in October. The suit-and-ties had expected a 1% rise in inventories. Elsewhere, concerns about the European debt crisis have been put on the back burner (again) after Portugal said it would not seek a bailout and Japan indicated it would buy euro zone bonds. As far as specific stocks, Seattle Genetics (SGEN, $16.62, up $0.80) is getting a pop after its CEO gave an update on one of its cancer drugs and said he expects fast-track approval from the FDA this quarter. Additionally, the company said it also received an $8 million fee from Pfizer (PFE, $18.30, up $0.04) for rights to use its cancer-fighting antibody-drug technology.